Company Filing History:
1 out of 15 
1 out of 12 
Years Active: 2025
Title: Mark Carr - Innovator in Alzheimer's Disease Treatment
Introduction
Mark Carr is a notable inventor based in Leicester, GB. He has made significant contributions to the field of biotechnology, particularly in the development of treatments for Alzheimer's disease. His innovative work has led to the creation of a unique patent that addresses critical health challenges.
Latest Patents
Mark Carr holds a patent for a humanised anti-n-truncated amyloid β monoclonal antibody. This invention relates to humanised antibodies that bind amyloid peptides, incorporating mutations in the heavy chain and/or light chain variable domains. These mutations enhance the binding activity of the antibodies, making them potentially useful in treating Alzheimer's disease.
Career Highlights
Throughout his career, Mark Carr has worked with several esteemed institutions. He has been associated with Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin, and LifeArc. His experience in these organizations has contributed to his expertise in the field of antibody development.
Collaborations
Mark has collaborated with notable professionals in his field, including Thomas Bayer and Preeti Bakrania. These partnerships have further enriched his research and development efforts.
Conclusion
Mark Carr's innovative work in developing humanised antibodies represents a significant advancement in the fight against Alzheimer's disease. His contributions to biotechnology continue to inspire future research and development in this critical area of health.